Nurse empowerment through Pharmacogenetics.
Jordana Carvalhaes de Moraes, Fernanda Daniela Dornelas Nunes, Fernanda Borchers Coeli-Lacchini and 3 others
PMID 32813781WHAT IT FOUND
In 67 Brazilian adults over 40, 37% carried CYP2C9 variants associated with intermediate drug metabolism, and 98.5% had used CYP2C9-metabolized drugs.
Reported adverse reactions did not differ by genotype.
Key findings
01Among 67 adults, 25 (37%) had CYP2C9 genotypes associated with intermediate metabolism.
0298.5% of participants had been exposed to drugs metabolized by CYP2C9, and 27.5% reported adverse events.
03Adverse reactions did not differ significantly between intermediate and extensive metabolizers (P=0.270).
STILL TO COME
How it was doneWhat they foundWhat it means for RNs
Read the rest of this summary
You get three full summaries a month, free, and we do not ask for a card. Search, the TL;DRs and your library stay unlimited either way.
What it does not show
Only 67 adults were studied, and they were university attendees rather than patients served by a health service, so serious adverse effects may have been missed. The study did not test a nurse-led intervention or clinical outcome, so it cannot show that pharmacogenetic information improves care. Intermediate metabolizer status was inferred only from CYP2C9 *2 and *3; other polymorphisms were not tested, so some people may be slow metabolizers. Adverse reactions were reported by participants and not stratified by type because the sample was too small. The cost estimate excluded labour, structural and private-sector costs, so it is not a full implementation cost.
The easy way to misread this
Do not read this as evidence that pharmacogenetic testing prevents adverse drug reactions. The study was descriptive, included 67 adults, and reported adverse reactions did not differ between intermediate and extensive metabolizers (P=0.270).